• Tubastatin A: Reading Cell-Death Signals

  2026-08-14

  Tubastatin A is a selective HDAC6 inhibitor whose value extends beyond simple viability assays. This article explains how a porcine cardiac-arrest study supports a multiparametric strategy for distinguishing pyroptosis, necroptosis, and myocardial recovery while defining practical limits for cancer, inflammation, and neuroprotection research.

• Otilonium Bromide: Mechanism, Uses & Limits

  2026-08-13

  Otilonium Bromide is a quaternary ammonium antimuscarinic agent for in vitro studies of cholinergic signaling and smooth muscle pharmacology. Its product specifications support controlled formulation and storage, while the cited SARS-CoV-2 NSP15 study does not establish antiviral activity for this compound.

• Apigenin Workflows for HDAC and Neuroprotection

  2026-08-13

  Apigenin supports two complementary research workflows: mechanistic oncology studies centered on HDAC inhibition, ROS, and DNA damage, and neurodegeneration assays focused on apoptosis and neuroinflammation. This guide converts those findings into practical dosing, controls, assay-selection, and troubleshooting strategies.

• Sphingosine-1-phosphate: Receptor-Context Assays

  2026-08-12

  Sphingosine-1-phosphate is a context-dependent lipid signal whose effects depend on receptor subtype, cell state, and assay design. This guide connects S1P biology with practical strategies for interpreting vascular, survival, and neuronal apoptosis experiments.

• Tubastatin A: Practical HDAC6 Inhibition Guide

  2026-08-12

  Learn how to deploy Tubastatin A as a selective HDAC6 inhibitor across cell, inflammation, cancer, neuroprotection, and cardiac injury workflows. The guide translates porcine resuscitation findings into assay design, dosing logic, controls, and troubleshooting steps without overstating translational certainty.

• SIRT1/2 Inhibitor IV: Mechanistic Assay Design

  2026-08-11

  SIRT1/2 Inhibitor IV (cambinol) is a cell-permeable dual SIRT1/SIRT2 inhibitor for dissecting deacetylation, lactylation, p53, tubulin, and hypoxia-linked biology. This article presents an assay-first framework that connects recent Ran lactylation findings with rigorous CNS and cancer research workflows.

• Prochlorperazine: Practical Research Workflows

  2026-08-11

  Prochlorperazine is a dopamine D2 receptor antagonist that supports coordinated melanoma, membrane-trafficking, and pharmacology workflows. This guide translates its concentration ranges, receptor breadth, and safety profile into practical assay design, controls, and troubleshooting decisions.

• Entinostat (MS-275) Experimental Workflow Guide

  2026-08-10

  Entinostat (MS-275) provides a selective class I HDAC1/3 perturbation strategy for connecting target engagement with cancer phenotypes and regeneration biology. This workflow guide shows how to prepare experiments, verify histone acetylation, compare cellular responses, and troubleshoot weak or misleading results.

• Nocodazole at the Microtubule–Genome Stability Interface

  2026-08-09

  Nocodazole provides a reversible way to connect microtubule dynamics, cell-cycle state, and genome-maintenance phenotypes. This translational framework integrates β-tubulin perturbation with findings on INO80-mediated postreplicative gap repair while clearly separating evidence from testable hypotheses.

• NADH Workflows for Redox and Mitochondrial Research

  2026-08-08

  Build reproducible redox assays with NADH, from micromolar cell-culture perturbations to mitochondrial electron transport chain research. This guide also shows how NADH supports hypoxia studies, disease models, and photocatalytic cancer therapy workflows while avoiding common stability and interpretation errors.

• Nicotinamide Adenine Dinucleotide (NAD+) Guide

  2026-08-07

  Nicotinamide Adenine Dinucleotide (NAD+) is a redox coenzyme, signaling substrate, and research reagent. Its biochemical value depends on separating NAD+ redox chemistry, NAD+-consuming enzymes, assay conditions, and the limited evidence for NAD+ supplementation in fatigue-related disorders.

• Ciprofloxacin Beyond Resistance: Mechanistic Innovations in

  2026-08-07

  Explore the molecular intricacies and advanced applications of Ciprofloxacin, a leading fluoroquinolone antibiotic, in cutting-edge research. This article unveils novel mechanistic insights, including nanoplatform-enabled delivery and immune modulation, setting it apart from standard antimicrobial resistance studies.

• M344: Advancing HDAC Inhibitor Strategies from Bench to Beds

  2026-08-06

  Explore how M344, a potent histone deacetylase inhibitor, is redefining translational research in cancer and viral latency. This thought-leadership analysis fuses mechanistic insight, peer-reviewed validation, and actionable workflow guidance—enabling researchers to overcome common pitfalls, drive assay reproducibility, and bridge the gap between preclinical promise and clinical impact.

• Prochlorperazine: Dopamine D2 Receptor Antagonist in Researc

  2026-08-06

  Prochlorperazine stands out as a robust dopamine D2 receptor antagonist, powering both cancer and antiviral experimental workflows. This guide reveals practical strategies, protocol optimization, and troubleshooting insights for maximizing reproducibility and impact in melanoma research and beyond.

• Astrocytic EAATs and Connexin 43 in Breakthrough Cancer Pain

  2026-08-05

  This study establishes a robust mouse model for breakthrough cancer pain (BTcP), revealing that spinal astrocytic EAAT1/2 downregulation and connexin 43 activation drive pain hypersensitivity. Targeting these astrocytic pathways with modulators such as ceftriaxone and Gap26 significantly alleviates pain, offering new mechanistic insights and experimental strategies for BTcP research.

694 records 8/47 page Previous Next First page 上5页 678910 下5页 Last page